Altamira Therapeutics Ltd
NASDAQ:CYTO
Altamira Therapeutics Ltd
NASDAQ:CYTO
Price:
1.416 USD
-5.6%
Market Closed
Updated:
May 10, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of CYTO.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CYTO
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
CYTO Competitors Multiples
Altamira Therapeutics Ltd Competitors
Altamira Therapeutics Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
2.6m USD | 0 | -0.6 | -0.3 | -0.3 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
724B USD | 20.2 | 117.9 | 57.9 | 65.7 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.1 | 44.1 | 32.9 | 36.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.4B USD | 4.2 | 9.4 | 11.5 | 15.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
330.5B USD | 5.4 | 143.3 | 35.6 | 58.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
191.8B GBP | 5 | 37.9 | 174.6 | 278.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
180.6B CHF | 3.4 | 11.4 | 8.7 | 12.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
179.5B CHF | 3.1 | 15.6 | 8.9 | 10.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.1B USD | 2.9 | -511.8 | 12.7 | 20.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
